PriceTargets.com logo

MAIA Biotechnology - MAIA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.26 As of 11/15/2024 01:00 AM ET
▲ +0.13 (6.10%)

This chart shows the closing price for MAIA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MAIA Biotechnology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MAIA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MAIA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MAIA Biotechnology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.26.

This chart shows the closing price for MAIA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in MAIA Biotechnology. This rating has held steady since February 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/21/2023Noble FinancialInitiated CoverageOutperform$14.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.81 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

MAIA Biotechnology logo
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $2.26
Low: $1.80
High: $2.29

50 Day Range

MA: N/A

52 Week Range

Now: $2.26
Low: $0.82
High: $5.99

Volume

357,025 shs

Average Volume

175,857 shs

Market Capitalization

$57.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of MAIA Biotechnology?

The following sell-side analysts have issued reports on MAIA Biotechnology in the last year:
View the latest analyst ratings for MAIA.

What is the current price target for MAIA Biotechnology?

0 Wall Street analysts have set twelve-month price targets for MAIA Biotechnology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for MAIA Biotechnology in the next year.
View the latest price targets for MAIA.

What is the current consensus analyst rating for MAIA Biotechnology?

MAIA Biotechnology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MAIA.

What other companies compete with MAIA Biotechnology?

Other companies that are similar to MAIA Biotechnology include Compass Therapeutics, Atai Life Sciences, Inozyme Pharma, Opthea and Inhibrx. Learn More about companies similar to MAIA Biotechnology.

How do I contact MAIA Biotechnology's investor relations team?

MAIA Biotechnology's physical mailing address is 444 WEST LAKE STREET SUITE 1700, CHICAGO IL, 60606. The company's listed phone number is 312-416-8592 and its investor relations email address is [email protected]. The official website for MAIA Biotechnology is www.MAIABiotech.com. Learn More about contacing MAIA Biotechnology investor relations.